Trial Exclusions May Skew RA Drug Comparisons

• by Andrea Surnit

• June 12, 2026

Healthcare utilization and costs in patients with rheumatoid arthritis using biologics or tofacitinib: a nationwide, population-based study

• by Yen-Ju Chen, Wei-Li Ho, Hsian-Min Chen, Yi-Ming Chen, Hsin-Hua Chen

• June 22, 2026

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

• by Kathryn Wighton

• June 11, 2026

• 2 min

Autoreactivity vs autoimmunity: characteristics of autoantigen-specific CD4 T-cells in rheumatoid arthritis and health.

• by James A. Stanway, Daniel Peters, Helen Waller, Jeremy Lakey, Henrique De Paula Lemos, Kristian Williams, Abbie Degnan, Julie Diboll, Abdul Mannan Baru, David Tough, Arthur G. Pratt, Catharien M.U. Hilkens, Amy E. Anderson, John D. Isaacs

• June 1, 2026